Eris Lifesciences Ltd initiated the process to fully consolidate its injectable manufacturing subsidiary, Swiss Parenterals, by acquiring the remaining 30% stake for ₹423.3 crore. The company announced the move in its stock exchange filing on Monday. Eris already owns 70% of the subsidiary.
Share Swap to Fund the Entire Transaction
The company will complete the acquisition entirely through a share swap. Eris plans to issue 23,06,372 equity shares on a preferential basis to Naishadh Shah, a director at Swiss Parenterals and the seller of the stake.
The issue price is ₹1,835.35 per share, based on an independent valuation. After the transaction closes, Swiss Parenterals will become a wholly owned subsidiary of Eris Lifesciences. Eris said the buyout will strengthen operational control, improve cost efficiencies, and enable full financial consolidation across the group. The deal is expected to close before 31 March 2026, subject to required approvals.
Swiss Parenterals Continues Strong Growth
Founded in 1997, Swiss Parenterals manufactures a wide range of parenteral products and supplies them to over 80 countries.
The company has shown consistent growth over the past three years:
*₹351 crore turnover in FY25
*₹283 crore in FY24
*₹221 crore in FY23
As reported by cnbctv18.com, the acquisition will allow Eris to integrate this expanding business segment more tightly into its overall operations.
